Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin, Gemcitabine, and Gefitinib in Advanced Urothelial Tract Carcinoma
NCT00041106Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2002
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 7 years. Started May 2002; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00041106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041106.